Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn ’s disease: a profile of its use
AbstractVedolizumab (Entyvio®), a humanized monoclonal antibody targeting the α4β7 integrin, is effective and generally well tolerated as an induction and maintenance therapy for adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional th erapy or a tumour necrosis factor (TNF)-α antagonist. Initially approved as a lyophilised powder for reconstitution and administration via intravenous infusion, more recently, a solution for subcutaneous injection has been developed (and approved in...
Source: Drugs and Therapy Perspectives - November 11, 2021 Category: Drugs & Pharmacology Source Type: research
Educate patients with medication overuse headache, and intervene, when necessary
AbstractMedication overuse headache (MOH) most commonly affects people with migraine, particularly in patients who overuse medications intended for short-term pain relief. Education is a very effective treatment option, however, many people need withdrawal support, especially those with psychiatric comorbidities or patients using opioids, barbiturates or benzodiazepines. Many patients also require longer-term migraine preventative medications, such as monoclonal antibodies against calcitonin gene-related peptide, which also show promise as a treatment for MOH. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 10, 2021 Category: Drugs & Pharmacology Source Type: research
Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study
DiscussionImmigrants were less likely than longstanding Canadian residents to have unplanned hospital visits. Among immigrants, those who were non-LP were less likely than those who were LP to have unplanned healthcare visits. However, unplanned healthcare visits related to bleeding were similar between groups. Several sociocultural factors and differing structural barriers may help to explain the observed differences in hospital visit rates. Failure to identify differences in bleeding events may relate to factors that preserve adherence to warfarin despite limited language proficiency. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 10, 2021 Category: Drugs & Pharmacology Source Type: research
Prescriber responses to alternative alert builds (AABs) designed for enduring drug shortages: a descriptive study
ConclusionIn general, acceptance rates and the number of triggered EMR alerts do not demonstrate consistent patterns that can be easily predicted. Other factors, including circumstantial context, may provide more insight into how AABs can be maximized to mitigate drug shortages. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 9, 2021 Category: Drugs & Pharmacology Source Type: research
What will be the role of molnupiravir in the treatment of COVID-19 infection?
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - November 5, 2021 Category: Drugs & Pharmacology Source Type: research
Acknowledgement to referees
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 28, 2021 Category: Drugs & Pharmacology Source Type: research
Correction to: Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
(Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 22, 2021 Category: Drugs & Pharmacology Source Type: research
Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a profile of its use
AbstractThe CD123-directed cytotoxin tagraxofusp (ELZONRIS®) is the first treatment approved in the EU for first-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults. BPDCN is a rare disease that affects mainly older patients and is usually treated with acute leukaemia-type multi-drug chemotherapy regimens followed, if possible, by stem cell transplantation (SCT). In the largest prospective trial conducted in BPDCN to date, treatment with tagraxofusp led to high rates of early and durable response in patients with previously untreated BPDCN, and enabled bridging to SCT in half of those who resp...
Source: Drugs and Therapy Perspectives - October 21, 2021 Category: Drugs & Pharmacology Source Type: research
Medication Reconciliation at Hospital Admission: Proactive Versus Retroactive Models
ConclusionThis study demonstrated that implementation of the proactive model was feasible. Compared with the retroactive model, the proactive model had a positive impact on preventing discrepancies with timeliness and efficiency. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 19, 2021 Category: Drugs & Pharmacology Source Type: research
Pharmacological management of psychoactive substance withdrawal syndrome
ConclusionsSubstitution therapy seems to be the foremost choice for the treatment of psychoactive substance withdrawal. However, other medications are available but poorly utilized. Practitioners can use the armory of other available medications to manage psychoactive substance withdrawal. Patients can broaden their medication choice. Voltage-gated ion channels are a promising niche to explore. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 19, 2021 Category: Drugs & Pharmacology Source Type: research
COVID-19: State of the Vaccination
AbstractThe emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 15, 2021 Category: Drugs & Pharmacology Source Type: research
Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia ™) in peanut allergy: a profile of its use
AbstractPeanut (Arachis hypogaea) allergen powder-dnfp (Palforzia ™; hereafter referred to as PTAH), is the first oral immunotherapy approved in the USA and European Commission for mitigating allergic reactions in children aged 4–17 years with peanut allergy. In the pivotal phase 3 studies in patients with peanut allergy, relative to placebo, PTAH significantl y desensitized to peanut protein and reduced severity of allergic reactions to accidental peanut exposure, together with improvements in food allergy-related quality of life. The clinical benefits of PTAH were maintained with continued treatment for up to 2 years...
Source: Drugs and Therapy Perspectives - October 12, 2021 Category: Drugs & Pharmacology Source Type: research
Don ’t despair over difficult-to-treat warts
AbstractCutaneous warts, common in children and immunocompromised patients, can be painful and socially and functionally restricting. Caused by several human papillomavirus types, they may resolve spontaneously or respond to traditional treatments. If not, pharmacological options for difficult-to-treat warts include intralesional and/or topical immunological and antiviral agents, with clearance of all warts achieved in many patients. Vaccines,Candida albicans antigen, vitamin D analogues, cidofovir, imiquimod and chemotherapeutics are worth considering. (Source: Drugs and Therapy Perspectives)
Source: Drugs and Therapy Perspectives - October 11, 2021 Category: Drugs & Pharmacology Source Type: research
Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
AbstractMetoclopramide is a prokinetic agent used to promote gastrointestinal motility. It is available for intramuscular, intravenous, subcutaneous and oral administration. In June 2020, metoclopramide nasal spray (MNS) 15 mg (administered 30 min before each meal and at bedtime for 2 –8 weeks), received FDA-approval for the acute and chronic management of diabetic gastroparesis (DG) in adults. Four studies that evaluated the efficacy and tolerability of MNS in patients with DG were identified, but none evaluated MNS 15 mg. Of the four studies, one found MNS more effective than metoclopramide tablets: per-protocol patien...
Source: Drugs and Therapy Perspectives - October 6, 2021 Category: Drugs & Pharmacology Source Type: research
Systematic review on the choice of antibiotics for management of complicated urinary tract bacterial infections and acute pyelonephritis
AbstractThe management of complicated urinary tract infections has been limited, with suboptimal success, treatment failure, recurrent infection, and the development of resistant bacterial strains. We reviewed the antimicrobial efficacy and safety and the microbial resistance of antibiotics for complicated urinary tract infections. This systematic review of 11 randomized controlled trials assessed the overall success rate and clinical cure rate of various antibiotics compared with conventional alternatives. Among the articles meeting inclusion criteria, we identified nine different agents, including ceftazidime –avibacta...
Source: Drugs and Therapy Perspectives - September 26, 2021 Category: Drugs & Pharmacology Source Type: research
